Quantitative trait locus

Singleron launches single cell eQTL analysis as part of their sequencing service

Retrieved on: 
Wednesday, January 25, 2023
Whole genome sequencing, WGS, Gene expression, Laboratory, Workflow, Data analysis, Knowledge, RNA, Bioinformatics, Quantitative trait locus, Genetic variation, Fine chemical

COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at Singleron Biotechnologies, a leader in single cell sequencing, have developed a new single cell eQTL analysis workflow that takes advantage of single cell RNA sequencing (scRNAseq) and whole genome sequencing (WGS) data to predict cell-type specific eQTLs.

Key Points: 
  • A new bioinformatic pipeline to investigate single cell eQTL analysis is now offered in the sequencing service from Singleron Biotechnologies.
  • COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at Singleron Biotechnologies , a leader in single cell sequencing, have developed a new single cell eQTL analysis workflow that takes advantage of single cell RNA sequencing (scRNAseq) and whole genome sequencing (WGS) data to predict cell-type specific eQTLs.
  • This resource is ideal for customers wanting to perform population studies and requires both wet lab and computational support for single cell eQTL analysis and adds a valuable addition in understanding the molecular mechanisms of disease.
  • It will complement the already established single cell multi-omics sequencing service from Singleron, to provide customers requiring an outsourced solution for their single cell sequencing.

Chinese Medical Journal Study Finds New Genetic Variant Linked to Pancreatic Cancer Prognosis

Retrieved on: 
Monday, January 9, 2023
Research, DNA, Single-nucleotide polymorphism, Pancreatic cancer, Malignancy, Patient, Prognosis, Chinese Medical Journal, Quantitative trait locus, SNP, Meta-analysis, Survival, Gene, Pharmaceutical industry, Vaccine

BEIJING, Jan. 9, 2023 /PRNewswire/ -- Pancreatic adenocarcinoma (PAAD) is a malignancy with an extremely poor prognosis and high fatality rate. Despite advances in medical technologies over the past decades, early detection and effective treatments are limited. Genetic factors considerably influence the overall survival of patients with PAAD. Naturally, several studies have attempted to discover genes associated with PAAD prognosis or overall survival. However, the findings were not consistent owing to limited sample sizes and the heterogeneity in studies' design.

Key Points: 
  • BEIJING, Jan. 9, 2023 /PRNewswire/ -- Pancreatic adenocarcinoma (PAAD) is a malignancy with an extremely poor prognosis and high fatality rate.
  • Naturally, several studies have attempted to discover genes associated with PAAD prognosis or overall survival.
  • Their paper, published in Volume 135, Issue 11 of the Chinese Medical Journal, was made available online on July 13, 2022.
  • Prof. Xiaoping Miao, senior author on the study, comments, "The regulatory genetic variants that affect PAAD prognosis are largely unknown.

Qualcomm Offers to Acquire Veoneer for $37 per Share in Cash

Retrieved on: 
Thursday, August 5, 2021
Amon, Chief executive officer, Research, U.S. Securities and Exchange Commission, Solution, Investment, Industry, Patent, Technology, Intellectual property, Security (finance), Internet, Magna, Engineering, Code-division multiple access, Quantitative computed tomography, COVID-19, Board, Quantitative trait locus, Orthogonal frequency-division multiple access, News, Sale, SEC, ADAS, SAN, Board of directors, Environment, Acquisition, Nasdaq, Traction, Forward-looking statement, Bank, Renewable energy

SAN DIEGO, Aug.5, 2021 /PRNewswire/ --Qualcomm Incorporated (NASDAQ: QCOM) today announced it has submitted an offer to acquire Veoneer for $37 per share, in an all-cash transaction.

Key Points: 
  • SAN DIEGO, Aug.5, 2021 /PRNewswire/ --Qualcomm Incorporated (NASDAQ: QCOM) today announced it has submitted an offer to acquire Veoneer for $37 per share, in an all-cash transaction.
  • Our offer has been approved by Qualcomm's Board of Directors, does not require Qualcomm stockholder approval, and has no financing conditions.
  • Qualcomm will fund the transaction with existing cash resources, and therefore, its offer is not subject to any financing contingency or condition.
  • Qualcomm is the world's leading wireless technology innovator and the driving force behind the development, launch, and expansion of 5G.